All Hyland's Baby Teething Tablets Recalled Over Belladonna Concerns — Physician’s First Watch

Medical News |
April 18, 2017

All Hyland's Baby Teething Tablets Recalled Over Belladonna Concerns

By Amy Orciari Herman

Edited by David G. Fairchild, MD, MPH

All lots of Hyland's Baby Teething Tablets and Hyland's Baby Nighttime Teething Tablets are being recalled because the amount of belladonna in the products may differ from that noted on their labels. Belladona has an anticholinergic effect and is potentially toxic when ingested.

In January 2017, the FDA issued an alert regarding the inconsistent amounts of belladona in Hyland's teething remedies and advised parents not to use them, given the potential risk to infants and children. The manufacturer did not agree to a recall at that time.

Now, the company notes that it stopped distributing the products in the U.S. in October 2016. The current recall, the company says, "ensures the removal of any possible remaining products that may be on store shelves."

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.